VXRT News and Press, Vaxart Inc. From 02/25/21

Vaxart (VXRT): Q4 GAAP EPS of -$0.13 misses by $0.07.Revenue of $0.36M (-90.8% Y/Y) misses by $3.99M.Cash and cash equivalents of $126.9 million as of December 31, 2020Press Release For further details see: Vaxart EPS misses by $0.07, misses on revenue

VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021 Cash and cash equivalents of $126.9 million as of December 31, 2020 Conference call and webcast focused on our COVID-19 strategy scheduled for T...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business updat...

Vaxart (NASDAQ: VXRT) brought investors high hopes over the past several months. Imagine a vaccine without the jab: That's Vaxart's specialty. The clinical-stage biotech company is developing oral vaccines for a variety of viruses -- including SARS-CoV-2, the virus that causes COVID...

r/WallStreetBets initiated the GameStop squeeze, but has targeted a number of other stocks as well. While the GME situation is not likely to repeat, it seems likely we'll see efforts to make similar moves. A number of stocks fit the pattern seen so far, providing interesting poten...

For some small biotechs , the race to develop a COVID-19 vaccine represented an opportunity to secure funding and establish partnerships that could serve as lifelines long after the pandemic. Two companies who have been eager to take advantage are Inovio Pharmaceuticals (NASDA...

For the biotech industry , 2020 was all about the race for a COVID-19 vaccine. By now, several have been authorized, a few additional candidates are beginning to cross the finish line ... and others have fallen by the wayside. After reporting preliminary phase 1 results for its tabl...

Vaxart (NASDAQ: VXRT) recently reported preliminary results from phase 1 study of its tablet COVID-19 vaccine candidate. Although there were some positive data in those results, many investors worried about the failure of the experimental vaccine to produce neutralizing antibodies i...

Vaxart (NASDAQ: VXRT) started out 2021 with its stock skyrocketing. However, most of those early gains evaporated after the biotech announced preliminary results from an early-stage clinical study evaluating the company's experimental tablet COVID-19 vaccine. In this Motley Fool L...

Short-sellers gained a lot of attention in recent days as they rushed to cover positions in rapidly rising stocks such as GameStop (NYSE: GME) . In this case, they lost their bets on the stock's decline -- and their money. But in some cases, the shorted stock does fall. And shor...